- Home
- POET vs PRTC Comparison
POET vs PRTC Comparison
Compare POET & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POET
- PRTC
- Stock Information
- Founded
- POET 1972
- PRTC 2015
- Country
- POET Canada
- PRTC United States
- Employees
- POET N/A
- PRTC N/A
- Industry
- POET Semiconductors
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- POET Technology
- PRTC Health Care
- Exchange
- POET Nasdaq
- PRTC Nasdaq
- Market Cap
- POET 369.0M
- PRTC 432.3M
- IPO Year
- POET N/A
- PRTC N/A
- Fundamental
- Price
- POET $4.34
- PRTC $18.50
- Analyst Decision
- POET Strong Buy
- PRTC Buy
- Analyst Count
- POET 2
- PRTC 1
- Target Price
- POET $6.25
- PRTC $45.00
- AVG Volume (30 Days)
- POET 728.7K
- PRTC 3.2K
- Earning Date
- POET 05-14-2025
- PRTC 04-30-2025
- Dividend Yield
- POET N/A
- PRTC N/A
- EPS Growth
- POET N/A
- PRTC N/A
- EPS
- POET N/A
- PRTC 0.21
- Revenue
- POET $199,477.00
- PRTC $4,828,000.00
- Revenue This Year
- POET $9,379.33
- PRTC $35.98
- Revenue Next Year
- POET $684.42
- PRTC $115.38
- P/E Ratio
- POET N/A
- PRTC $8.24
- Revenue Growth
- POET N/A
- PRTC 44.98
- 52 Week Low
- POET $1.65
- PRTC $13.30
- 52 Week High
- POET $7.79
- PRTC $32.98
- Technical
- Relative Strength Index (RSI)
- POET 49.84
- PRTC 58.17
- Support Level
- POET $4.31
- PRTC $17.80
- Resistance Level
- POET $4.68
- PRTC $19.17
- Average True Range (ATR)
- POET 0.25
- PRTC 0.48
- MACD
- POET -0.04
- PRTC 0.13
- Stochastic Oscillator
- POET 28.03
- PRTC 74.72
About POET POET Technologies Inc.
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.